Following the completion of this financing, the high-profile organisms will establish a headquarters in the Bay of Life Port in the Depressed Mountain Region of Hangzhou to consolidate resources to accelerate the development of corporate genetic treatment pipelines and technological platforms. On 6 May, CSN reported that the genotherapy company, which has an animal model platform, has completed nearly S$ A billion in funding, co-sponsored by sub-account capital and Chinese capital, followed b...